Effect of dapagliflozin on bone metabolism in patients with type 2 diabetes

Effect of dapagliflozin on bone metabolism in patients with type 2 diabetes - Effect of dapagliflozin on bone metabolism

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000032220

Enrollment

Registered

2018-04-15

Start date

2015-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes

Interventions

Treated with dapagliflozin

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Female type 2 diabetes patients aged 20 years or over and under 70 years old.

Exclusion criteria

Exclusion criteria: The patients with severe endocrine or metabolic disorders including diabetes ketoacidosis, BMI over 45, post bariatric and metabolic surgery. The patients who have severe liver or cardiovascular disorder, malignant tumor, skeletal diseases. female patients with pregnant or brest-feeding. The patients treated with anti-osteoporosis drugs, gulcocorticoid or diuretics.

Design outcomes

Primary

Measure	Time frame
Calcium/phosphate parameter	—

Secondary

Measure	Time frame
glucose and lipid metabolism	—

Countries

Japan

Contacts

Public ContactItsuro Endo

Tokushima University Department of Chronomedicine

endoits@tokushima-u.ac.jp088-633-7120

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026